<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6628">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00999544</url>
  </required_header>
  <id_info>
    <org_study_id>09-0446</org_study_id>
    <secondary_id>R01DA027031</secondary_id>
    <nct_id>NCT00999544</nct_id>
  </id_info>
  <brief_title>Aprepitant Effects on Oxycodone Response</brief_title>
  <official_title>New Neural Drug Targets: An Evaluation of the Effects of Aprepitant on the Response to Oxycodone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kentucky</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Addressing the issue of opioid dependence and tolerance has public health implications for
      the treatment of opioid abuse (both heroin as well as pharmaceutical opioids) and for the
      treatment of pain. Recent preclinical data suggest a role for Substance P (NK-1) receptors
      in modulating both the acute and chronic response to opioids. The objective of this study is
      to determine whether pretreatment with aprepitant, a selective neurokinin-1 (NK-1)
      antagonist can reduce the direct response to an opioid agonist (oxycodone) on measures
      related to abuse liability and reinforcing effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy adult volunteers with histories of illicit opioid use by the intranasal and oral
      routes will be admitted to this 6-week inpatient, crossover study. They will participate in
      15 experimental test sessions, each lasting approximately 6.5 hours, during which they will
      receive a range of acute doses of aprepitant, including placebo, followed by challenge with
      oxycodone or placebo (given intranasally or orally). Multi-dimensional outcomes, including
      physiological (blood pressure, oxygen saturation, pupil diameter), subjective
      (questionnaires related to mood, abuse liability) and observer ratings will be collected
      repeatedly throughout each session. Data will be analyzed using parametric approaches to
      within-subject designs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Abuse Liability Proxy</measure>
    <time_frame>42 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Visual analog scale ratings (from 0-100) on the subject-rated measure of &quot;How much do you like the drug?&quot; with higher scores indicating greater abuse liability (and 100 anchored with &quot;extremely&quot; and zero indicating none anchored with &quot;none at all.&quot; Data were collected across multiple time points but the peak maximum score was used for the primary outcome measure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aprepitant Side Effects</measure>
    <time_frame>42 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Narcotic Abuse</condition>
  <arm_group>
    <arm_group_label>Aprepitant, Placebo, Oxycodone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a full crossover study in which all participants will receive every planned study drug condition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprepitant</intervention_name>
    <description>Aprepitant (0, 40, 200 mg, p.o.) to be given in combination with a range of oxycodone doses (p.o. 20 and 40 mg, i.n. 15 and 30 mg) and double-dummy placebo with each aprepitant and oxycodone being tested once in each subject (a total of 15 conditions) in random order</description>
    <arm_group_label>Aprepitant, Placebo, Oxycodone</arm_group_label>
    <other_name>Emend</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo condition</description>
    <arm_group_label>Aprepitant, Placebo, Oxycodone</arm_group_label>
    <other_name>Lactose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <description>Oxycodone was administered at 15 and 30 mg intranasally and at 20 and 40 mg orally once after each of the oral pretreatment conditions (placebo and active aprepitant)</description>
    <arm_group_label>Aprepitant, Placebo, Oxycodone</arm_group_label>
    <other_name>Roxicet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recreational user of opioids

          -  Healthy

          -  Ages 18-55 years old

          -  Able to provide informed consent

        Exclusion Criteria:

          -  Ongoing medical or psychiatric condition that would be contraindicated for
             participation

          -  Past 30 day use of and P4503A4 inhibitor
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon L Walsh, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Walsh SL, Heilig M, Nuzzo PA, Henderson P, Lofwall MR. Effects of the NK1 antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusers. Addict Biol. 2013 Mar;18(2):332-43. doi: 10.1111/j.1369-1600.2011.00419.x. Epub 2012 Jan 19.</citation>
    <PMID>22260216</PMID>
  </results_reference>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 19, 2013</lastchanged_date>
  <firstreceived_date>October 20, 2009</firstreceived_date>
  <firstreceived_results_date>November 13, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Sharon Walsh</investigator_full_name>
    <investigator_title>Director Center on Drug and Alcohol Research</investigator_title>
  </responsible_party>
  <keyword>opioid</keyword>
  <keyword>oxycodone</keyword>
  <keyword>NK1 antagonist</keyword>
  <keyword>aprepitant</keyword>
  <keyword>intranasal</keyword>
  <keyword>abuse</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All recruitment was conducted through a research clinic at a public university.</recruitment_details>
      <pre_assignment_details>Subjects were initially screened for inclusion/exclusion criteria. Fifteen subjects signed the screening consent but only nine were qualified to participate and signed the study consent. One subject left the study before receiving any interventions.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Within-subject Crossover Design</title>
          <description>All subjects received exposure to every study condition in random order. During each of 15 separate test sessions, subjects received pretreatment with aprepitant (0, 40 or 200 mg) followed by a single challenge with a oxycodone (15 or 30, intranasal; 20 or 40 mg) or placebo. The fifteen dose conditions were administered in random order and each subject was exposed to each dose combination once.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Crossover Within Subject</title>
          <description>All subjects were exposed to every condition.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="32.3" spread="3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Abuse Liability Proxy</title>
        <description>Visual analog scale ratings (from 0-100) on the subject-rated measure of &quot;How much do you like the drug?&quot; with higher scores indicating greater abuse liability (and 100 anchored with &quot;extremely&quot; and zero indicating none anchored with &quot;none at all.&quot; Data were collected across multiple time points but the peak maximum score was used for the primary outcome measure.</description>
        <time_frame>42 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Prior laboratory-based within subject studies of the pharmacodynamic response to opioid challenges. The within subject data analysis does not lend itself to reporting data in the format provided below.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo-Placebo (in and po)</title>
            <description>All subjects received exposure to this study condition once.</description>
          </group>
          <group group_id="O2">
            <title>Aprepitant 40 mg - Placebo</title>
            <description>All subjects received exposure to this study condition once.</description>
          </group>
          <group group_id="O3">
            <title>Aprepitant 200 mg- Placebo</title>
            <description>All subjects received exposure to this study condition once.</description>
          </group>
          <group group_id="O4">
            <title>Placebo- 15 mg Oxycodone Intranasal</title>
            <description>All subjects received exposure to this study condition once.</description>
          </group>
          <group group_id="O5">
            <title>Placebo- 30 mg Oxycodone Intranasal</title>
            <description>All subjects received exposure to this study condition once.</description>
          </group>
          <group group_id="O6">
            <title>Placebo- 20 mg Oxycodone Oral</title>
            <description>All subjects received exposure to this study condition once.</description>
          </group>
          <group group_id="O7">
            <title>Placebo - 40 mg Oxycodone Oral</title>
            <description>All subjects received exposure to this study condition once.</description>
          </group>
          <group group_id="O8">
            <title>Aprepitant 40 mg- 15 mg Oxycodone Intranasal</title>
            <description>All subjects received exposure to this study condition once.</description>
          </group>
          <group group_id="O9">
            <title>Aprepitant 40 mg - 30 mg Oxycodone Intranasal</title>
            <description>All subjects received exposure to this study condition once.</description>
          </group>
          <group group_id="O10">
            <title>Aprepitant 40 mg- 20 mg Oxycodone Oral</title>
            <description>All subjects received exposure to this study condition once.</description>
          </group>
          <group group_id="O11">
            <title>Aprepitant 40 mg - 40 mg Oxycodone Oral</title>
            <description>All subjects received exposure to this study condition once.</description>
          </group>
          <group group_id="O12">
            <title>Aprepitant 200 mg - 15 mg Oxycodone Intranasal</title>
            <description>All subjects received exposure to this study condition once.</description>
          </group>
          <group group_id="O13">
            <title>Aprepitant 200 mg - 30 mg Oxycodone Intranasal</title>
            <description>All subjects received exposure to this study condition once.</description>
          </group>
          <group group_id="O14">
            <title>Aprepitant 200 mg- 20 Oxycodone Oral</title>
            <description>All subjects received exposure to this study condition once.</description>
          </group>
          <group group_id="O15">
            <title>Aprepitant 200 mg- 40 Oxycodone Oral</title>
            <description>All subjects received exposure to this study condition once.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="8"/>
                  <measurement group_id="O3" value="8"/>
                  <measurement group_id="O4" value="8"/>
                  <measurement group_id="O5" value="8"/>
                  <measurement group_id="O6" value="8"/>
                  <measurement group_id="O7" value="8"/>
                  <measurement group_id="O8" value="8"/>
                  <measurement group_id="O9" value="8"/>
                  <measurement group_id="O10" value="8"/>
                  <measurement group_id="O11" value="8"/>
                  <measurement group_id="O12" value="8"/>
                  <measurement group_id="O13" value="8"/>
                  <measurement group_id="O14" value="8"/>
                  <measurement group_id="O15" value="8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Abuse Liability Proxy</title>
            <description>Visual analog scale ratings (from 0-100) on the subject-rated measure of &quot;How much do you like the drug?&quot; with higher scores indicating greater abuse liability (and 100 anchored with &quot;extremely&quot; and zero indicating none anchored with &quot;none at all.&quot; Data were collected across multiple time points but the peak maximum score was used for the primary outcome measure.</description>
            <units>units on a scale (points 0-100)</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.197" spread="0.197"/>
                  <measurement group_id="O2" value="0.483" spread="0.397"/>
                  <measurement group_id="O3" value="0.159" spread="0.159"/>
                  <measurement group_id="O4" value="7.678" spread="2.656"/>
                  <measurement group_id="O5" value="17.450" spread="4.275"/>
                  <measurement group_id="O6" value="9.850" spread="5.090"/>
                  <measurement group_id="O7" value="16.646" spread="4.203"/>
                  <measurement group_id="O8" value="8.543" spread="2.892"/>
                  <measurement group_id="O9" value="15.092" spread="4.706"/>
                  <measurement group_id="O10" value="13.281" spread="4.009"/>
                  <measurement group_id="O11" value="17.244" spread="4.788"/>
                  <measurement group_id="O12" value="17.195" spread="4.897"/>
                  <measurement group_id="O13" value="28.211" spread="4.365"/>
                  <measurement group_id="O14" value="8.196" spread="2.667"/>
                  <measurement group_id="O15" value="26.322" spread="3.702"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
              <group_id>O11</group_id>
              <group_id>O12</group_id>
              <group_id>O13</group_id>
              <group_id>O14</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <groups_desc>Area-under-the-curve (AUC) scores were derived from time course data and analyzed using two-factor ANOVA [aprepitant dose (3 levels)x oxycodone dose (3 levels)].
All analyses were conducted using SAS 9.1 for Windows (SAS Institute Inc., Cary, NC, USA) and were considered significant when P 0.05.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aprepitant Side Effects</title>
        <time_frame>42 days</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Within-subject Crossover Design</title>
          <description>All subjects received exposure to every study condition in random order. This was not a parallel group design.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No significant adverse effects occurred. No adverse events led to study drop-out.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Sharon Walsh</name_or_title>
      <organization>University of Kentucky</organization>
      <phone>859-257-6485</phone>
      <email>sharon.walsh@uky.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
